PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

United States

Arkansas Children's Hospital, Little Rock, Arkansas

University Medical Center of Southern Nevada, Las Vegas, Nevada

University of North Carolina (UNC), Chapel Hill, North Carolina

East Carolina University, Greenville, North Carolina